Back to Search Start Over

Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

Authors :
Economopoulou, Panagiota Pantazopoulos, Anastasios Spathis, Aris and Kotsantis, Ioannis Kyriazoglou, Anastasios Kavourakis, George Zakopoulou, Roubini Chatzidakis, Ioannis Anastasiou, Maria Prevezanou, Maria Resteghini, Carlo Licitra, Lisa and Bergamini, Cristiana Colombo, Elena Caspani, Francesca and Denaro, Nerina Vecchio, Stefania Bonomo, Pierluigi Cossu Rocca, Maria Bertolini, Federica Ferrari, Daris Psyrri, Amanda Bossi, Paolo
Publication Year :
2022

Abstract

Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.od......2127..90b2371887a8f468c1a8495d999b3199